Medical Journals

A Validated Gene Expression Model of High-risk Multiple Myeloma is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.

Authors:
  • Shaughnessy John D
  • Zhan Fenghuang
  • Burington Bart E
  • Huang Yongsheng
  • Colla Simona
  • Hanamura Ichiro
  • Stewart James P
  • Kordsmeier Bob
  • Randolph Christopher
  • Williams David R
  • Xiao Yan
  • Xu Hongwei
  • Epstein Joshua
  • Anaissie Elias
  • Krishna Somashekar G
  • Cottler-Fox Michele
  • Hollmig Klaus
  • Mohiuddin Abid
  • Pineda-Roman Mauricio
  • Tricot Guido
  • van Rhee Frits
  • Sawyer Jeffrey
  • Alsayed Yazan
  • Walker Ronald
  • Zangari Maurizio
  • Crowley John
  • Barlogie Bart

From: Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. shaughnessyjohn@uams.edu

Blood

  • Publish Date: Mar 2007
  • ISSN: 0006-4971
  • Volume: 109
  • Issue: 6
  • Pages: 2276-84
  • Medium: Print
  • Language: English
  • Citation (JAMA): Shaughnessy John D, Zhan Fenghuang, Burington Bart E, et al. A Validated Gene Expression Model of High-risk Multiple Myeloma is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. Blood Mar 2007;109:2276-84

Abstract

To molecularly define high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols. Using log-rank tests of expression quartiles, 70 genes, 30% mapping to chromosome 1 (P < .001), were linked to early disease-related death. Importantly, most up-regulated genes mapped to chromosome 1q, and down-regulated genes mapped to chromosome 1p. The ratio of mean expression levels of up-regulated to down-regulated genes defined a high-risk score present in 13% of patients with shorter durations of complete remission, event-free survival, and overall survival (training set: hazard ratio [HR], 5.16; P < .001; test cohort: HR, 4.75; P < .001). The high-risk score also was an independent predictor of outcome endpoints in multivariate analysis (P < .001) that included the International Staging System and high-risk translocations. In a comparison of paired baseline and relapse samples, the high-risk score frequency rose to 76% at relapse and predicted short postrelapse survival (P < .05). Multivariate discriminant analysis revealed that a 17-gene subset could predict outcome as well as the 70-gene model. Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.

Mesh Headings (Keywords): Aged, Chromosome Mapping, Chromosomes, Human, Pair 1, Cohort Studies, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Models, Genetic, Multigene Family, Multiple Myeloma, Recurrence, Risk Factors, Survival Rate


Check for Full Text / PubMed Unique Identifier (PMID): 17105813


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.